We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Acumen Pharmaceuticals, Inc. (ABOS - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Acumen Pharmaceuticals, Inc. is one of 913 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Acumen Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ABOS' full-year earnings has moved 5.9% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ABOS has gained about 2.8% so far this year. Meanwhile, stocks in the Medical group have gained about 1.2% on average. This shows that Acumen Pharmaceuticals, Inc. is outperforming its peers so far this year.
Amarin (AMRN - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 2%.
The consensus estimate for Amarin's current year EPS has increased 92.7% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Acumen Pharmaceuticals, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 438 individual stocks and currently sits at #84 in the Zacks Industry Rank. On average, this group has gained an average of 3.3% so far this year, meaning that ABOS is slightly underperforming its industry in terms of year-to-date returns. Amarin is also part of the same industry.
Acumen Pharmaceuticals, Inc. and Amarin could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Acumen Pharmaceuticals, Inc. (ABOS - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Acumen Pharmaceuticals, Inc. is one of 913 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Acumen Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ABOS' full-year earnings has moved 5.9% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ABOS has gained about 2.8% so far this year. Meanwhile, stocks in the Medical group have gained about 1.2% on average. This shows that Acumen Pharmaceuticals, Inc. is outperforming its peers so far this year.
Amarin (AMRN - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 2%.
The consensus estimate for Amarin's current year EPS has increased 92.7% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Acumen Pharmaceuticals, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 438 individual stocks and currently sits at #84 in the Zacks Industry Rank. On average, this group has gained an average of 3.3% so far this year, meaning that ABOS is slightly underperforming its industry in terms of year-to-date returns. Amarin is also part of the same industry.
Acumen Pharmaceuticals, Inc. and Amarin could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.